News | June 30, 2023
Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Fully equipped labs with 75-member team set-up and made operational in <100 days
Study efficacy measures will include the expression of dystrophin protein and motor function.
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai
Subscribe To Our Newsletter & Stay Updated
